MAGIC: Multicenter Glaucoma Study Investigating Standalone Canaloplasty
Study Details
Study Description
Brief Summary
A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight Sciences) in patients with mild to moderate primary open-angle glaucoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: iTrack Advance Ab-interno canaloplasty utilizing the iTrack Advance microcatheter device (Nova Eye, Inc.) |
Device: Ab-interno canaloplasty utilizing the iTrack Advance device
360 degree microcatheterization and viscodilation of Schlemm's canal
|
| Active Comparator: OMNI Surgical System Ab-interno canaloplasty utilizing the OMNI Surgical System |
Device: Ab-interno canaloplasty utilizing the OMNI Surgical System
360 degree microcatheterization and viscodilation of Schlemm's canal
|
Outcome Measures
Primary Outcome Measures
- The mean reduction in unmedicated Intraocular pressure (IOP) at 12 months post-intervention compared to baseline [12 months]
- Percentage of eyes achieving a 20% or greater reduction in unmedicated Intraocular pressure (IOP) at 12 months compared to baseline and without any other intervention (medication or secondary surgery) [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female subjects, 22 years or older at the time of surgery
-
Diagnosed with mild to moderate primary open angle glaucoma
-
Candidate for canaloplasty surgery: i.e., catheterization of Schlemm's canal and subsequent viscodilation of Schlemm's canal, without trabeculotomy
-
Intolerance to medical therapy OR need/willingness to reduce medications
-
At the Screening Visit, IOP of ≤ 30 mmHg while on 1-4 ocular hypotensive medications
-
At the Baseline Visit, unmedicated IOP ≥ 21mmHg and ≤ 33 mmHg, and ≥ 3mmHg higher than medicated IOP
-
Shaffer grade of ≥ 3 in all four quadrants
-
Endothelial cell density >2000 (cells/mm2)
-
Central corneal thickness ≥ 490µm and ≤ 600 µm
-
Able and willing to comply with the study procedures and attend all follow-up visits
-
Understands and signs the informed consent
Exclusion Criteria:
- Any of the following prior treatments for glaucoma (study eye):
- Laser trabeculoplasty
- Selective Laser Trabeculoplasty (SLT) conducted within 6-months of the Screening Visit ii. Prior Argon Laser Trabeculoplasty
-
iStent or iStent Inject within 180 days of the Screening Visit
-
Endocyclophotocoagulation (ECP) or Micropulse laser
-
Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma draining device/valve
-
Prior canaloplasty (ab interno and ab externo)
-
Prior goniotomy, or trabeculotomy (ab externo and ab interno)
-
Hydrus microstent
-
Suprachoroidal stent (e.g., Cypass, iStent Supra)
-
Concurrent IOP-lowering procedure other than use of the iTrack Advance canaloplasty device OR the OMNI Surgical System at the time of surgery (e.g., ECP, CPC, etc.)
-
Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma, pigmentary glaucoma or pseudoexfoliative glaucoma
-
Cataract surgery within 6 months of the Screening Visit in the study eye
-
History of fellow eye with cataract surgery within 30 days of Screening
-
Subjects at significant risk by a washout of ocular hypotensive medication, and/or subjects where the unmedicated IOP is expected to exceed the upper limit of 33 mmHg
-
Use of systemic medications (either current, within 30 calendar days of Screening exam, or anticipated) that may cause an increase in IOP, (e.g., systemic steroids including inhaled and oral steroids used on a regular basis)
-
Ocular and/or systemic diseases that could affect the corneal endothelium (such as corneal endothelial dystrophy, intraocular inflammation and infection, or congenital abnormalities)
-
History of penetrating keratoplasty or another corneal transplant
-
BCVA of 20/200 or worse in the fellow eye not due to cataract
-
Previous treatment with OMNI or iTrack (Note: permitted if fellow eye only was treated)
-
BCVA of 20/50 or worse in the study eye not due to posterior capsular opacification
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Nova Eye, Inc.
- Nova Eye Medical GmbH
Investigators
- Principal Investigator: Shamil Patel, MD, MBA, Eye Physicians and Surgeons of Arizona
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NE 05021